Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-12			5-day change	1st Jan Change
55.81 ^CNY	-1.31%		-1.69%	-1.57%

Mar. 03	Frontage Laboratories, Inc. acquired Teddy Clinical Research Laboratory Co., Ltd from Hangzhou Tigermed Consulting Co., Ltd and Jiaxing Xinge Medical Consulting Co., Ltd.	CI
Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT

Beijing Trimmune Biotech Co., Ltd. announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd

Published on 02/13/2026 at 03:57 pm EST

S&P Capital IQ

HANGZHOU TIGERMED CONSULTING CO., LTD

-1.31%

Beijing Trimmune Biotech Co., Ltd. announced that it has received in a round of funding from new investor, Hangzhou Tigermed Consulting Co., Ltd on February 13, 2026. The company issued convertible preferred shares in the transaction.

Latest news about Hangzhou Tigermed Consulting Co., Ltd

Mar. 03	Frontage Laboratories, Inc. acquired Teddy Clinical Research Laboratory Co., Ltd from Hangzhou Tigermed Consulting Co., Ltd and Jiaxing Xinge Medical Consulting Co., Ltd.	CI
Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT
Feb. 13	Beijing Trimmune Biotech Co., Ltd. announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	CI
Jan. 29	Tigermed Consulting Forecasts Upto 204% Jump in 2025 Profit; Shares Rise 8%	MT
Jan. 29	Hangzhou Tigermed Consulting sees 2025 net profit up 105-204% Y/Y	RE
Jan. 29	Tigermed Consulting Expects Up to 204% Surge in 2025 Profit	MT
Nov. 25	HKEX says JP Morgan's long position in Hangzhou Tigermed Consulting H-shares increased to 7.71%	RE
25-10-28	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-28	Tigermed Consulting's Q3 Profit Soars 99%	MT
25-10-28	Hangzhou Tigermed Consulting posts qtrly revenue RMB1.78 billion	RE
25-10-10	Hangzhou Tigermed Consulting to Sell Research Lab Firm to Frontage Unit	MT
25-10-10	Hangzhou Tigermed Consulting announces disposal of Teddy Clinical Research Laboratory (Shanghai)	RE
25-08-29	Hangzhou Tigermed Consulting's Attributable Profit Slides 22% in H1	MT
25-08-28	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-29	Tigermed completes acquisition of Japanese CRO Micron	RE

Chart Hangzhou Tigermed Consulting Co., Ltd

Duration

Period

Chart Hangzhou Tigermed Consulting Co., Ltd

300347: Dynamic Chart

Company Profile

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.

Employees

10,185

Sector

Biotechnology & Medical Research

Calendar

Mar. 31 - Earnings release - Annual 2025

More about the company